// App-Quantinova.ai

3547 : Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial.

Researchers

Presenter

  • Robert J. Mayer

Principal Investigators

  • Takayuki Yoshino

  • Alfredo Falcone

  • Rocio Garcia-Carbonero

  • Guillem Argiles

  • Azzurra Damiani

  • Marc Peeters

  • Lukas Makris

  • Alberto Zaniboni

  • Yasuhiro Shimada

  • Kentaro Yamazaki

  • Yoshito Komatsu

  • Howard S. Hochster

  • Heinz-Josef Lenz

  • Ben Tran

  • Robert Winkler

  • Paul Bebeau

  • Mona M. Wahba

  • Eric Van Cutsem

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • National Cancer Center, EPOC, Chiba, Japan

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • IRCCS San Martino - IST, Genoa, Italy

  • Antwerp University Hospital, Edegem, Belgium

  • Stathmi, Inc., New Hope, PA

  • Fondazione Poliambulanza, Brescia, Italy

  • National Cancer Center Hospital, Tokyo, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Japan, Shizuoka, Japan

  • Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Japan, Sapporo, Japan

  • Department of Medical Oncology, Yale University School of Medicine, New Haven, CT

  • University of Southern California, Los Angeles, CA

  • Royal Melbourne Hospital, Melbourne, Australia

  • Taiho Oncology Inc., Princeton, NJ

  • Taiho Oncology Inc., Princeton, NJ

Locations

  • Japan

  • Italy

  • Spain

  • Australia

  • United States

  • Belgium

Companies

  • Stathmi, Inc.

  • Taiho Oncology Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01607957TAS-102

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved